The Ave–Rec Trial: Phase II Trial of PDL1/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4/N1-2 Rectal Cancer
The Ave-Rec phase II study demonstrated that avelumab after LCCRT is deliverable and tolerable, with significant imaging responses and a major pathologic response rate. Tumoral immune cell subsets/checkpoint expression was predictive of pathologic response. The addition of immune checkpoint inhibitors warrants further evaluation in patients with LARC.
Authors
- Samuel Y. Ngan
- David Goldstein (ORCID: https://orcid.org/0000-0001-6142-3291)
- Sanjeev Gill
- Catherine Mitchell (ORCID: https://orcid.org/0000-0001-5596-9511)
- Alexander G. Heriot (ORCID: https://orcid.org/0000-0001-9846-8776)
- Robert G. Ramsay (ORCID: https://orcid.org/0000-0001-5003-0433)
- Sara Roth (ORCID: https://orcid.org/0000-0002-6510-181X)
- Kasmira Wilson (ORCID: https://orcid.org/0000-0002-4601-5270)
- Eva Segelov (ORCID: https://orcid.org/0000-0002-4410-6144)
- Maria Farrell
- Milton Mui (ORCID: https://orcid.org/0000-0002-1507-8228)
- Jeanne Tie (ORCID: https://orcid.org/0000-0001-9244-2057)
- Emma Link (ORCID: https://orcid.org/0000-0002-5461-3799)
- Nick Pavlakis (ORCID: https://orcid.org/0000-0002-1738-0316)
- Jeremy Shapiro (ORCID: https://orcid.org/0009-0007-9290-8145)
- Rachel Wong (ORCID: https://orcid.org/0000-0002-4926-5689)
- Michael Michael (ORCID: https://orcid.org/0000-0002-0593-2662)
- Andrew Strickland (ORCID: https://orcid.org/0000-0002-0374-8669)
Institutions
- University of Bern (CH)
- Bern University of Applied Sciences (CH)
- The University of Melbourne (AU)
- Royal North Shore Hospital (AU)
- Peter MacCallum Cancer Centre (AU)
- Monash Medical Centre (AU)
- The Alfred Hospital (AU)
- Cabrini Hospital (AU)
- Eastern Health (AU)
- Prince of Wales Hospital (AU)
- Monash Health (AU)
- Monash University (AU)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-0705
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00